Loading clinical trials...
Loading clinical trials...
A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Conditions
Interventions
[203Pb]VMT-α-NET
[212Pb]VMT-α-NET
Locations
17
United States
Mayo Clinic
Jacksonville, Florida, United States
Biogenix Molecular
Miami, Florida, United States
The University of Chicago
Chicago, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
University of Kentucky
Lexington, Kentucky, United States
Johns Hopkins
Baltimore, Maryland, United States
Start Date
September 27, 2023
Primary Completion Date
November 26, 2029
Completion Date
December 26, 2029
Last Updated
April 23, 2026
NCT06790706
NCT04609592
NCT04727723
NCT05262556
NCT05987176
NCT01842165
ClinicalTrials at Perspectivetherapeutics
CONTACT
(206) 676-0900clinicaltrials@perspectivetherapeutics.comLead Sponsor
Perspective Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions